Reactivating NK Cells in Treating Refractory Head and Neck Cancer

Phase 1/2 Unknown 31 enrolled National University Hospital, Singapore

NaSingle-groupOpen-labelTreatment

Summary

This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.

Timeline

Start: 2015-07
Primary completion: 2019-08
Completion: 2019-08

Publications

Lim CM, Liou A, Poon M, Koh LP, Tan LK, Loh KS, Petersson BF, Ting E, Campana D, Goh BC, Shimasaki N. Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma. Cancer Immunol Immunother. 2022 Sep;71(9):2277-2286. doi: 10.1007/s00262-022-03158-9. Epub 2022 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	—	Intravenous
Subject	TROCULEUCEL	Cell therapy	1e+06 cells/kg	—
Subject	TROCULEUCEL	Cell therapy	1e+07 cells/kg	—

Reactivating NK Cells in Treating Refractory Head and Neck Cancer

Summary

Timeline

Publications

Drugs

Indications